JRAB inhibitors represent a class of chemical compounds that specifically target and inhibit the activity of the JRAB (junctional Rab13 binding protein) protein. JRAB is a crucial component in cellular processes, particularly in the context of intracellular trafficking and cytoskeletal dynamics. These inhibitors are designed to interfere with the protein-protein interactions facilitated by JRAB, thereby disrupting its functional pathways. By inhibiting JRAB, these compounds can alter the cellular architecture and impede the transportation of vesicles within the cell. The detailed mechanisms through which JRAB inhibitors exert their effects often involve complex interactions with the Rab GTPases, particularly Rab13, which is known to play a significant role in endocytic and exocytic processes. These interactions are essential for maintaining the integrity of various cellular structures and for the precise delivery of cargo within the cellular milieu.
The molecular design of JRAB inhibitors typically involves structures that can effectively bind to the active sites or the interaction domains of the JRAB protein, preventing its association with Rab13 and other binding partners. This binding specificity is achieved through a combination of computational modeling, high-throughput screening, and structure-activity relationship (SAR) studies, which help in optimizing the affinity and selectivity of the inhibitors. Additionally, the biochemical and biophysical properties of JRAB inhibitors are carefully tuned to ensure they can permeate cellular membranes and reach their intracellular targets efficiently. Research into JRAB inhibitors often includes detailed analyses of their effects on cellular morphology, vesicular transport pathways, and the overall homeostasis of the cell. These studies provide invaluable insights into the fundamental roles of JRAB in cellular function and the potential broader implications of its inhibition in biological systems.
Items 1 to 10 of 11 total
画面:
| 製品名 | CAS # | カタログ # | 数量 | 価格 | 引用文献 | レーティング |
|---|---|---|---|---|---|---|
Cytochalasin D | 22144-77-0 | sc-201442 sc-201442A | 1 mg 5 mg | $145.00 $442.00 | 64 | |
アクチン重合を阻害し、アクチン細胞骨格およびMICALの細胞骨格形成における役割に影響を与えることで、MICALを阻害する可能性がある。 | ||||||
Latrunculin A, Latrunculia magnifica | 76343-93-6 | sc-202691 sc-202691B | 100 µg 500 µg | $260.00 $799.00 | 36 | |
アクチンフィラメントの動態を変化させ、アクチン調節におけるMICALの機能に影響を与えることで、MICALを阻害する可能性がある。 | ||||||
NSC 23766 | 733767-34-5 | sc-204823 sc-204823A | 10 mg 50 mg | $148.00 $597.00 | 75 | |
細胞骨格の再構築においてMICALタンパク質と相互作用する低分子量GTPaseであるRac1の阻害剤。 | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $182.00 $693.00 | 88 | |
アクチン細胞骨格のダイナミクスに影響を及ぼし、間接的にMICALが媒介するアクチンの調節に影響を及ぼす可能性があるROCK阻害剤。 | ||||||
CK 666 | 442633-00-3 | sc-361151 sc-361151A | 10 mg 50 mg | $315.00 $1020.00 | 5 | |
アクチン重合に影響を及ぼし、アクチンのダイナミクスにおけるMICALの役割と相互作用する可能性があるArp2/3複合体の阻害剤。 | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
ヒストン脱アセチル化酵素を阻害し、クロマチン構造の変化につながり、MICALの転写を抑制する可能性がある。 | ||||||
Mithramycin A | 18378-89-7 | sc-200909 | 1 mg | $54.00 | 6 | |
DNAに結合し、RNA合成を阻害し、MICALを含む可能性のある様々な遺伝子の転写を減少させる可能性がある。 | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $56.00 $260.00 $980.00 | 163 | |
プロテアソーム阻害剤は、タンパク質の分解経路を変化させることで、間接的にタンパク質のレベルに影響を与える可能性があり、MICALを含む可能性がある。 | ||||||
α-Amanitin | 23109-05-9 | sc-202440 sc-202440A | 1 mg 5 mg | $260.00 $1029.00 | 26 | |
RNAポリメラーゼIIを特異的に阻害し、MICALをコードするmRNAの転写を抑制する可能性がある。 | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
mTORを阻害する複合体を形成し、タンパク質合成に幅広い影響を及ぼす可能性があり、MICALの発現に影響を与える可能性がある。 | ||||||